Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accustem SciencesACUT -28.89%29 3-Year EPS without NRI Growth Rate is 29.30% as of Jun. 2026, which is at its 10-year median of 29.30. GuruFocus rates ACUT with a GF Score™ of 29/100. Among 1,160 Biotechnology companies, Accustem Sciences ranks better than 65.09% on this metric.
During the past 3 years, the average EPS without NRI Growth Rate was 29.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
During the past 4 years, the highest 3-Year average EPS without NRI Growth Rate of Accustem Sciences was 29.30% per year. The lowest was 29.30% per year. And the median was 29.30% per year.
Accustem Sciences (OTCPK:ACUT) 3-Year EPS without NRI Growth Rate Explanation
EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.
Accustem Sciences 3-Year EPS without NRI Growth Rate Related Terms
ACUT vs BIXT, CMND, CASIF: 3-Year EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, Accustem Sciences's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accustem Sciences 3-Year EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Accustem Sciences's 3-Year EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where Accustem Sciences's 3-Year EPS without NRI Growth Rate falls into.
Accustem Sciences 3-Year EPS without NRI Growth Rate Calculation
This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.
What does a 3-Year EPS without NRI Growth Rate of 29.30% mean?
Accustem Sciences (ACUT) has a 3-Year EPS without NRI Growth Rate of 29.30% as of Jun. 2026. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Accustem Sciences and its competitors. This is near median its historical median of 29.30. Over the past decade, Accustem Sciences' 3-Year EPS without NRI Growth Rate has ranged from 29.30 to 29.30. According to the industry distribution chart, Accustem Sciences ranks #405 out of 1160 companies in the Biotechnology industry, placing it in the top 34.9%.
Is Accustem Sciences' 3-Year EPS without NRI Growth Rate too high?
Accustem Sciences' current 3-Year EPS without NRI Growth Rate of 29.30% is near median its 10-year median of 29.30. Over the past 10 years, this metric has ranged from a low of 29.30 to a high of 29.30. The Biotechnology industry median 3-Year EPS without NRI Growth Rate is 16.20. Accustem Sciences' value of 29.30% is 80.9% above this industry median. Based on the distribution chart, Accustem Sciences ranks #405 out of 1160 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Accustem Sciences has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Accustem Sciences' 3-Year EPS without NRI Growth Rate compare to BIXT and CMND?
According to the Biotechnology industry distribution chart, Accustem Sciences ranks #405 out of 1160 companies for 3-Year EPS without NRI Growth Rate. This puts Accustem Sciences in the upper half of its industry. The industry median 3-Year EPS without NRI Growth Rate is 16.20. Accustem Sciences' value of 29.30% is 80.9% above this benchmark. Historically, Accustem Sciences' own 3-Year EPS without NRI Growth Rate has ranged from 29.30 to 29.30 over the past decade. While the company's 10-year median is 29.30 vs. the industry median of 16.20, Accustem Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EPS without NRI Growth Rate for a Biotechnology company?
The median 3-Year EPS without NRI Growth Rate among Biotechnology companies is 16.20, based on 1,160 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accustem Sciences's current 3-Year EPS without NRI Growth Rate of 29.30% is 80.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EPS without NRI Growth Rate mean?
A high 3-Year EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EPS without NRI Growth Rate is the 3-year average growth rate of EPS without NRI. View historical data for Accustem Sciences and its competitors. For the Biotechnology industry, the median 3-Year EPS without NRI Growth Rate is 16.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accustem Sciences's current 3-Year EPS without NRI Growth Rate is 29.30%, which is near median its own 10-year median of 29.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accustem Sciences stock overvalued right now?
Accustem Sciences (ACUT) has a current 3-Year EPS without NRI Growth Rate of 29.30%. The current 3-Year EPS without NRI Growth Rate is 29.30%, which is near median its 10-year median of 29.30 and 80.9% above the Biotechnology industry median of 16.20. Accustem Sciences' overall GF Score™ is 29/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EPS without NRI Growth Rate calculated?
3-Year EPS without NRI Growth Rate is calculated from a company's financial statements. For Accustem Sciences (ACUT), the current 3-Year EPS without NRI Growth Rate is 29.30% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accustem Sciences Inc is a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the millions of people who are diagnosed with cancer each year. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services.
29GF Score
Get the complete analysis for ACUT
3-Year EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ACUT has been successfully added to your 
